161 related articles for article (PubMed ID: 32855818)
21. Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity.
Mori R; Yuzawa M; Akaza E; Haruyama M
Jpn J Ophthalmol; 2013 Jul; 57(4):365-71. PubMed ID: 23665979
[TBL] [Abstract][Full Text] [Related]
22. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
[TBL] [Abstract][Full Text] [Related]
23. Impact of Polyp Regression on 2-year Outcomes of Intravitreal Aflibercept Injections: A Treat-and-Extend Regimen for Polypoidal Choroidal Vasculopathy.
Morizane-Hosokawa M; Morizane Y; Kimura S; Shiode Y; Hirano M; Doi S; Toshima S; Hosogi M; Fujiwara A; Shiraga F
Acta Med Okayama; 2018 Aug; 72(4):379-385. PubMed ID: 30140086
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy.
Cho HJ; Kim JW; Lee DW; Cho SW; Kim CG
Eye (Lond); 2012 Mar; 26(3):426-33. PubMed ID: 22173075
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with polyp regression after intravitreal ranibizumab injections for polypoidal choroidal vasculopathy.
Cho HJ; Han SY; Kim HS; Lee TG; Kim JW
Jpn J Ophthalmol; 2015 Jan; 59(1):29-35. PubMed ID: 25373450
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy.
Komuku Y; Iwahashi C; Gomi F
Jpn J Ophthalmol; 2020 May; 64(3):265-270. PubMed ID: 32206935
[TBL] [Abstract][Full Text] [Related]
27. Distinct Responsiveness to Intravitreal Ranibizumab Therapy in Polypoidal Choroidal Vasculopathy With Single or Multiple Polyps.
Suzuki M; Nagai N; Shinoda H; Uchida A; Kurihara T; Tomita Y; Kamoshita M; Iyama C; Tsubota K; Ozawa Y
Am J Ophthalmol; 2016 Jun; 166():52-59. PubMed ID: 27017997
[TBL] [Abstract][Full Text] [Related]
28. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
Ngo WK; Chee WK; Tan CS; Lim TH
BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
[TBL] [Abstract][Full Text] [Related]
29. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
30. Factors predicting 2-year treatment results of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good baseline visual acuity.
Mori R; Tanaka K; Yuzawa M
Medicine (Baltimore); 2018 Jun; 97(25):e11188. PubMed ID: 29924037
[TBL] [Abstract][Full Text] [Related]
31. Comparison of Conbercept with Ranibizumab for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion.
Li F; Sun M; Guo J; Ma A; Zhao B
Curr Eye Res; 2017 Aug; 42(8):1174-1178. PubMed ID: 28441077
[TBL] [Abstract][Full Text] [Related]
32. [Ranibizumab and aflibercept for diabetic macular edema-retrospective study with real-life data after 12 months].
Holbach B; Zeman F; Helbig H; Gamulescu MA
Ophthalmologe; 2020 Jul; 117(7):687-692. PubMed ID: 31705192
[TBL] [Abstract][Full Text] [Related]
33. One-year outcome of combination therapy with intravitreal aflibercept and photodynamic therapy for polypoidal choroidal vasculopathy.
Weng HY; Huang TL; Chang PY; Wang JK
BMC Pharmacol Toxicol; 2019 May; 20(1):29. PubMed ID: 31088543
[TBL] [Abstract][Full Text] [Related]
34. One-year outcomes of fixed-dosing Aflibercept therapy for pre treated and naive polypoidal choroidal vasculopathy patient.
Choo HG; Lee JH; Oh HS; Kim SH; You YS; Kwon OW
BMC Ophthalmol; 2021 Feb; 21(1):94. PubMed ID: 33602156
[TBL] [Abstract][Full Text] [Related]
35. Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy.
Peng Y; Zhang X; Li M; Liu B; Mi L; Zuo C; Wen F
Drug Des Devel Ther; 2018; 12():339-345. PubMed ID: 29497280
[TBL] [Abstract][Full Text] [Related]
36. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
[TBL] [Abstract][Full Text] [Related]
37. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
38. Intravitreal aflibercept for submacular hemorrhage secondary to neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Kim JH; Kim CG; Lee DW; Yoo SJ; Lew YJ; Cho HJ; Kim JY; Lee SH; Kim JW
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):107-116. PubMed ID: 31741044
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
40. OPTICAL COHERENCE TOMOGRAPHY PREDICTORS OF SHORT-TERM VISUAL ACUITY IN EYES WITH MACULAR EDEMA SECONDARY TO RETINAL VEIN OCCLUSION TREATED WITH INTRAVITREAL CONBERCEPT.
Tang F; Qin X; Lu J; Song P; Li M; Ma X
Retina; 2020 Apr; 40(4):773-785. PubMed ID: 30640282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
